
News|Articles|November 1, 2010
Formulary Digital Edition November 2010
Attention deficit hyperactivity disorder: More than a child's disorder; Focus on lurasidone; Agents in late-stage development for the treatment of multiple sclerosis
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
When it comes to quality measures, fewer is viewed as better, says Ben Shirley of PQA | Part 2
3
Don’t let ‘sleepmaxxing’ keep you up at night: Results from the 2025 American Academy of Sleep Medicine survey on sleep tracking
4
Myqorzo is now available for rare heart condition at a $108,400 annual price
5























